160 related articles for article (PubMed ID: 12808442)
1. Potent antitumor activity of IL-13 cytotoxin in human pancreatic tumors engineered to express IL-13 receptor alpha2 chain in vivo.
Kawakami K; Kawakami M; Husain SR; Puri RK
Gene Ther; 2003 Jul; 10(13):1116-28. PubMed ID: 12808442
[TBL] [Abstract][Full Text] [Related]
2. Effect of interleukin (IL)-4 cytotoxin on breast tumor growth after in vivo gene transfer of IL-4 receptor alpha chain.
Kawakami K; Kawakami M; Husain SR; Puri RK
Clin Cancer Res; 2003 May; 9(5):1826-36. PubMed ID: 12738741
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-13 receptor alpha2 chain: a potential biomarker and molecular target for ovarian cancer therapy.
Kioi M; Kawakami M; Shimamura T; Husain SR; Puri RK
Cancer; 2006 Sep; 107(6):1407-18. PubMed ID: 16902988
[TBL] [Abstract][Full Text] [Related]
4. Specifically targeted killing of interleukin-13 (IL-13) receptor-expressing breast cancer by IL-13 fusion cytotoxin in animal model of human disease.
Kawakami K; Kawakami M; Puri RK
Mol Cancer Ther; 2004 Feb; 3(2):137-47. PubMed ID: 14985454
[TBL] [Abstract][Full Text] [Related]
5. A novel role of interleukin-13 receptor alpha2 in pancreatic cancer invasion and metastasis.
Fujisawa T; Joshi B; Nakajima A; Puri RK
Cancer Res; 2009 Nov; 69(22):8678-85. PubMed ID: 19887609
[TBL] [Abstract][Full Text] [Related]
6. Analysis of antitumor activity of an interleukin-13 (IL-13) receptor-targeted cytotoxin composed of IL-13 antagonist and Pseudomonas exotoxin.
Kioi M; Kawakami K; Puri RK
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6231-8. PubMed ID: 15448012
[TBL] [Abstract][Full Text] [Related]
7. Interleukin 4 receptor on human lung cancer: a molecular target for cytotoxin therapy.
Kawakami M; Kawakami K; Stepensky VA; Maki RA; Robin H; Muller W; Husain SR; Puri RK
Clin Cancer Res; 2002 Nov; 8(11):3503-11. PubMed ID: 12429641
[TBL] [Abstract][Full Text] [Related]
8. Internalization property of interleukin-4 receptor alpha chain increases cytotoxic effect of interleukin-4 receptor-targeted cytotoxin in cancer cells.
Kawakami K; Kawakami M; Leland P; Puri RK
Clin Cancer Res; 2002 Jan; 8(1):258-66. PubMed ID: 11801567
[TBL] [Abstract][Full Text] [Related]
9. Analysis of interleukin-13 receptor alpha2 expression in human pediatric brain tumors.
Kawakami M; Kawakami K; Takahashi S; Abe M; Puri RK
Cancer; 2004 Sep; 101(5):1036-42. PubMed ID: 15329913
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-13 receptor alpha2 chain in human head and neck cancer serves as a unique diagnostic marker.
Kawakami M; Kawakami K; Kasperbauer JL; Hinkley LL; Tsukuda M; Strome SE; Puri RK
Clin Cancer Res; 2003 Dec; 9(17):6381-8. PubMed ID: 14695138
[TBL] [Abstract][Full Text] [Related]
11. Tumor cells secreting IL-13 but not IL-13Ralpha2 fusion protein have reduced tumorigenicity in vivo.
Ma HL; Whitters MJ; Jacobson BA; Donaldson DD; Collins M; Dunussi-Joannopoulos K
Int Immunol; 2004 Jul; 16(7):1009-17. PubMed ID: 15184346
[TBL] [Abstract][Full Text] [Related]
12. Role of interleukin-13 in cancer, pulmonary fibrosis, and other T(H)2-type diseases.
Joshi BH; Hogaboam C; Dover P; Husain SR; Puri RK
Vitam Horm; 2006; 74():479-504. PubMed ID: 17027527
[TBL] [Abstract][Full Text] [Related]
13. IL-13 receptor-targeted cytotoxin cancer therapy leads to complete eradication of tumors with the aid of phagocytic cells in nude mice model of human cancer.
Kawakami K; Kawakami M; Puri RK
J Immunol; 2002 Dec; 169(12):7119-26. PubMed ID: 12471149
[TBL] [Abstract][Full Text] [Related]
14. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
O'Malley BW; Li D; McQuone SJ; Ralston R
Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
[TBL] [Abstract][Full Text] [Related]
15. Gene transfer of interleukin 13 receptor alpha2 chain dramatically enhances the antitumor effect of IL-13 receptor-targeted cytotoxin in human prostate cancer xenografts.
Kawakami K; Husain SR; Bright RK; Puri RK
Cancer Gene Ther; 2001 Nov; 8(11):861-8. PubMed ID: 11773976
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-13 receptor-targeted cancer therapy in an immunodeficient animal model of human head and neck cancer.
Kawakami K; Kawakami M; Joshi BH; Puri RK
Cancer Res; 2001 Aug; 61(16):6194-200. PubMed ID: 11507072
[TBL] [Abstract][Full Text] [Related]
17. Evidence that IL-13R alpha2 chain in human glioma cells is responsible for the antitumor activity mediated by receptor-directed cytotoxin therapy.
Kawakami K; Kioi M; Liu Q; Kawakami M; Puri RK
J Immunother; 2005; 28(3):193-202. PubMed ID: 15838375
[TBL] [Abstract][Full Text] [Related]
18. Combined effects of radiation and interleukin-13 receptor-targeted cytotoxin on glioblastoma cell lines.
Kawakami K; Kawakami M; Liu Q; Puri RK
Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):230-7. PubMed ID: 16111594
[TBL] [Abstract][Full Text] [Related]
19. In vivo overexpression of IL-13 receptor alpha2 chain inhibits tumorigenicity of human breast and pancreatic tumors in immunodeficient mice.
Kawakami K; Kawakami M; Snoy PJ; Husain SR; Puri RK
J Exp Med; 2001 Dec; 194(12):1743-54. PubMed ID: 11748276
[TBL] [Abstract][Full Text] [Related]
20. Adenoviral vector-mediated gene transfer of IL-13Ralpha2 chain followed by IL-13 cytotoxin treatment offers potent targeted therapy for cytotoxin-resistant cancers.
Saito M; Murata T; Watanabe K; Kawakami K; Suzuki M; Koji T; Puri RK; Kitazato K; Kobayashi N
Int J Cancer; 2005 Aug; 116(1):1-8. PubMed ID: 15756691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
